Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ClariPi develops FDA-cleared and CE-marked AI-powered software solutions that enhance the quality of CT images—especially low-dose or ultra-low-dose scans—by removing noise while preserving anatomical detail. Their flagship product, ClariCT.AI, has been validated with over a million patient images. Other products include automated reporting tools for lung diseases like emphysema/COPD/COVID‑19 pneumonia (ClariPulmo), bone health/osteoporosis risk assessment from CTs (ClariOsteo), breast density analysis from mammograms (ClariSIGMAM), and contrast agent boosting in CTs without increasing dose/exposure to patients (ClariACE). Clinical studies have demonstrated efficacy in improving diagnostic confidence at lower radiation doses.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on ClariPi.